Fundraising FoxDomain Associates — 2014 Investments
5 investments dated 2014 · listed companies and verified rows first · show all
Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome.
BiotechHealthtechMedical DevicesSan Diego, US
Han Cao(Executive Officer)Gulsen Kama(Executive Officer)Mark Oldakowski(Executive Officer)inJonathan Dixon(Executive Officer)inR. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)in
Board seatBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015
Co-investorsHudson Bay
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)
BoardM Bolyard(Director)Brian Dovey(Director)in
Co-investors1315 CapitalAisling CapitalRevelation PartnersRoundTable Healthcare PartnersHealthCare Ventures, LLCLongwood Fund+2 more
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)
Co-investorsARCH Venture PartnersBayMed Venture PartnersCross Creek AdvisorsEric F. ThiessenExcel Venture ManagementHeran Partners+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Benvenue MedicalXagenic
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.